Drug Discovery World

JUNE 15, 2023

ACROBiosystems, through ACRO Certify and under its Aneuro brand, has launched in vivo electrophysiology solutions for neuroscience research with Diagnostic Biochips. Together, the two companies are committed to a collaborative effort to accelerate neurological drug discovery and commercialisation.

In-Vivo 52

In-Vivo Drugs Branding Protein 52

Worldwide Clinical Trials

NOVEMBER 27, 2023

Casgevy, the commercial product formerly known as exa-cel, is administered by taking stem cells out of a patient’s bone marrow and editing a gene in the cells in a laboratory, with the modified cells then infused back into the patient after conditioning treatment to prepare the bone marrow. In June 2023, the U.S.

Gene Editing 174

Gene Editing Gene Gene Therapy In-Vivo 174

XTalks

APRIL 14, 2022

Conventional in vitro and in vivo studies are used in the drug development pipeline. However, could there be another way for developing biomedical products using in silico technology? Therefore, companies can evaluate their drug candidates or medical device products in “virtual patients” before assessing them in humans.

Trials 98

Trials In-Vivo In-Vitro Clinical Trials 98

Pharmaceutical Technology

MARCH 29, 2023

According to Sara Reci, analyst at GlobalData, many late-stage pipeline products for obesity emulate what is currently on the market, and employ the GLP-1 mechanism of action. In vivo data to date suggests therapeutic plasma levels of VK2735 may be achieved via oral dosing. Following the announcement, Brian Lian, Ph.D,

Drugs 264

Drugs In-Vivo Marketing Trials 264

Pharmaceutical Technology

APRIL 13, 2023

Significant collaborative R&D programmes that are likely to be affected include Takeda’s partnership with Codexis for AAV-based gene therapy for Fabry disease and Takeda’s $3.6bn dollar deal with Poseida for the development of nonviral in vivo gene therapy programmes for the hereditary bleeding disorder haemophilia A.

Gene Therapy 243

Gene Therapy Marketing Gene In-Vivo 243

Drug Discovery Today

NOVEMBER 5, 2020

London, November 4th, 2020: NanoMab Technology Limited, a privately held biopharmaceutical company focussing on cancer precision therapies, today announced that it had received CTA Acceptance from the Medicines Healthcare products Regulatory Agency (MHRA) to carry out a Phase II clinical Study for its NM-01 product.

In-Vivo 40

In-Vivo Production Medicine 40

Pharmaceutical Technology

SEPTEMBER 14, 2022

As an autologous cell therapy, manufacturing the infusion product is a highly specialised process involving tumour harvest and the extraction and large-scale ex vivo expansion of TILs. Tumour-infiltrating lymphocyte (TIL) therapy has been investigated as a treatment modality for melanoma for almost 20 years. months versus 3.1

Immune Response 246

Immune Response In-Vivo Production Manufacturing 246

Pharmaceutical Technology

OCTOBER 14, 2022

The AVATAR AI technology will mimic the tumour microenvironment ex vivo and provide capabilities that support the therapeutic products’ development with improved potency and persistence, as well as reduced cell exhaustion. Xcellbio said that the AVATAR AI technology uses the tight environmental control of the AVATAR product family.

Gene Therapy 130

Gene Therapy Gene Development Manufacturing 130

Pharmaceutical Technology

MARCH 24, 2023

Generation Bio will also receive payments in future development, regulatory and commercial milestones, along with royalties on worldwide net sales of immune cell-targeted and liver-targeted products. Both companies will use the partnership for advancing in vivo immune cell targeting as a new class of genetic medicines.

Genetics 130

Genetics Medicine Development In-Vivo 130

Roots Analysis

FEBRUARY 27, 2024

How is the genome editing market landscape evolving: Currently, there is an evident increase in demand for complex biological therapies (including regenerative medicine products), which has created an urgent need for robust genome editing techniques. The global genome editing market is anticipated to grow at a CAGR of 12.6%

Genome 40

Genome Genomics Gene Gene Editing 40

Camargo

DECEMBER 22, 2021

One of Camargo’s differentiating offerings is the portfolio analysis, a high-level, integrated evaluation of the scientific, medical, regulatory, and commercial viability of each product within a sponsor’s portfolio. Each product is unique, and so is the associated development strategy. Why Conduct a Portfolio Analysis?

Bioequivalency 169

Bioequivalency Production Genotoxicity In-Vivo 169

Pharmaceutical Technology

MAY 18, 2023

Other investors include Investissement Québec, Omega Funds, Cowen Healthcare Investments, CTI Life Sciences Fund III, Northleaf Capital Partners, BVF Partners and Vivo Capital. Net proceeds from the transaction are expected to be used to finance the clinical development of enGene’s lead product, intravesical detalimogene voraplasmid (EG-70).

Gene Therapy 130

Gene Therapy Gene In-Vivo Life Science 130

Pharmaceutical Technology

SEPTEMBER 14, 2022

Currently, the company is making investments and obtaining crucial aspects of commercial-scale production and radioisotope supply. The company is also concluding more than 200 in vivo studies to gain insights and discover new drug candidates that could provide therapeutic radioisotopes for tumour-linked antigens.

In-Vivo 130

In-Vivo Clinical Trials Clinical Trials Engineer 130

Pharmaceutical Technology

AUGUST 17, 2022

oRNA molecules have been demonstrated to possess increased stability in vivo compared to linear mRNA and can potentially create more quantities of therapeutic proteins within the body. . Merck will also make royalty payments on any approved products developed out of the partnership.

RNA 147

RNA Vaccination Vaccine In-Vivo 147

Pharmaceutical Technology

SEPTEMBER 29, 2022

Sanofi will also make tiered royalty payments on net sales of products resulting from the collaboration in the future. Under the agreement, Sanofi will receive non-exclusive rights to Scribe’s CRISPR by Design platform of wholly-owned enzymes for developing ex vivo NK cell therapies.

Development 130

Development In-Vivo Genome Genomics 130

Drug Discovery World

APRIL 10, 2024

The Food and Drug Administration (FDA) Investigational New Drug (IND) clearance for ECUR-506 makes it the first in vivo gene insertion programme authorised for clinical investigation in infants in the US. The post FDA approves first in vivo gene insertion programme in infants appeared first on Drug Discovery World (DDW).

In-Vivo 80

In-Vivo FDA Approval Gene Gene Editing 80

Pharmaceutical Technology

MAY 18, 2023

KSQ will receive future payments of up to $510m on achieving all milestones during the agreement period, along with potential net sales royalties on any commercial product that is the result of the partnership. Takeda will make an upfront payment and provide an investment in the double-digit millions of dollars to KSQ.

Gene Therapy 130

Gene Therapy In-Vivo Gene Genetics 130

Camargo

NOVEMBER 11, 2020

Unpacking the (Black) Box: Antares Licenses Urology Product with Boxed Warning. When the FDA requires a product’s labeling to include a boxed warning (also called a “black box warning” because the text is surrounded by black border), the potential market value of the drug often drops severely. In October, the U.S.

Development 242

Development Bioequivalency Generic Drugs Production 242

pharmaphorum

OCTOBER 8, 2021

The cell therapy field is showing no signs of slowing down, with huge investment and excitement around next generation products and their clinical validation in solid tumour indications. This year, we’ll be specifically focusing on next generation cell therapies and discussing: Novel in vivo delivery.

In-Vivo 52

In-Vivo Gene Manufacturing Marketing 52

Drug Discovery World

MARCH 7, 2024

Ginkgo is also working with Sensible Biotechnologies to develop an in vivo microbial mRNA manufacturing platform. Additionally, Ginkgo announced the successful completion of a manufacturing optimisation program with Biogen, focused on redefining the industry standard for manufacturing recombinant adeno-associated virus (AAV)-based vectors.

Gene Therapy 52

Gene Therapy RNA Engineer Gene 52

Drug Discovery World

MAY 29, 2023

The company previously participated in the first human trial of a gene therapy drug candidate for Menkes disease, and recently partnered with Stand Up Therapeutics to produce and supply gene therapy products for the treatment of paralysis. “As The new location is part of Edinburgh Technopole, a Pioneer Group in Midlothian Science Zone.

Gene Therapy 52

Gene Therapy In-Vivo Gene Sales 52

Drug Discovery World

JANUARY 25, 2024

The research will include studies to assess the effects of Vaxxinity’s active immunotherapies on undisclosed proteins implicated with bone and muscle growth through in vitro and in vivo experiments, and animal models established by UCF.

Medicine 52

Medicine Research In-Vivo In-Vitro 52

Drug Discovery World

JANUARY 3, 2023

Under the terms of the agreement, Mersana will develop novel ADC product candidates against up to two targets utilising its Immunosynthen platform to conjugate proprietary antibodies from Merck KGaA, Darmstadt, Germany. . Mersana will receive an upfront payment of $30 million.

Antibody 52

Antibody Development Research Drugs 52

Drug Discovery World

JANUARY 31, 2024

Support for danegapitide’s potential With safety data derived from over 500 clinical trial participants, robust toxicology data, and strong non-clinical in vitro and in vivo efficacy results, there is strong support for danegaptide’s potential to address the clinical core ocular pathologies of vascular leakage and capillary breakdown.

Clinical Trials 52

Clinical Trials Clinical Trials In-Vivo In-Vitro 52

Drug Discovery World

FEBRUARY 13, 2024

It has demonstrated efficacy in in vitro and in vivo models of fibrosis, as well as favourable safety and pharmacokinetic profiles in Phase I clinical studies. It has demonstrated efficacy in in vitro and in vivo models of fibrosis, as well as favourable safety and pharmacokinetic profiles in Phase I clinical studies.

Drugs 52

Drugs In-Vivo In-Vitro Medicine 52

BioTech 365

SEPTEMBER 2, 2020

SAN DIEGO and BOSTON, Sept. 02, 2020 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc.

DNA 40

DNA In-Vivo Protein Gene 40

Drug Discovery World

JANUARY 18, 2024

Poolbeg Pharma, a biopharmaceutical company focused on the development and commercialisation of medicines targeting diseases with a high unmet medical need, has announced promising in vivo results for POLB 001 in addressing cancer immunotherapy-induced cytokine release syndrome (CRS). million cases of cancer by 2030 1,2.

In-Vivo 64

In-Vivo Antibody Clinical Trials Clinical Trials 64

Drug Discovery World

JUNE 27, 2023

We look forward to continuing our productive collaboration with our colleagues at IRBM in this compelling area of research.” Italian contract research organisation IRBM has signed a new agreement with Merck & Co Inc (MSD outside the USA and Canada) to continue their collaboration in the peptide therapeutics area.

In-Vivo 52

In-Vivo In-Vitro Engineer Protein 52

The Pharma Data

JANUARY 17, 2021

Based in Seattle, Washington, Sana focuses on in vivo and ex vivo cell engineering platforms to develop therapies for cancer, diabetes, cardiovascular disease, CNS disorders, and genetic diseases. Early-stage companies are often years, often a decade or longer, from a marketable product.

In-Vivo 52

In-Vivo Marketing Engineer Genetics 52

Drug Discovery World

FEBRUARY 22, 2024

in 2023, fuelled by the FDA approval of its CRISPR-based ex vivo cell therapy Casgevy. Moderna and Pfizer’s market capitalisation decline was due to the diminishing demand for their Covid-19 products. The top 20 global biopharmaceutical companies have reported 1.6% market capitalisation growth to $3.67 billion for 2023.

Marketing 52

Marketing FDA Approval In-Vivo Sales 52

Drug Discovery World

MARCH 12, 2024

MJ : From the first known reference to medicinal use of plants on a Mesoptamian clay tablet written during the third millennium BC to the FDA approval of the blockbuster anticancer drug Taxol in the 1990s, natural products from plants have been at the forefront of efforts to overcome human diseases, such as cancers, hypertension, and pain.

Medicine 59

Medicine Production Drugs In-Vivo 59

pharmaphorum

FEBRUARY 23, 2021

Advance Cutting-Edge Research and Development with Next-Generation Cell Therapies, to Deliver Best-in-Class Products to Patients in Need. Implement logic and develop ‘decision-making’ cells: create robust, controllable activation in vivo with University of Pennsylvania and Ludwig Institute for Cancer Research Lausanne.

In-Vivo 52

In-Vivo Engineer Development Production 52

Drug Discovery World

JUNE 16, 2023

Our partners are leading companies (Conveyxo, Exo Biologics, Livedrop, Genflow Biosciences, Orgenesis, Theracell Advanced Biotechnology, Cylix Group) for each step of the production of ATMPs, which will then be developed and clinically evaluated by BioSenic. The ISCT 2023 Annual Meeting took place in Paris, France from May 31 to June 3 2023.

Manufacturing 52

Manufacturing In-Vivo Production Compliance 52

The Pharma Data

JANUARY 17, 2021

Joe Dupere, CEO of Ixaka, commented: “Ixaka’s broad offering of integrated cell and gene therapy capabilities, encompassing cell-based products and an innovative in vivo gene delivery platform, provides a strong foundation for our ambitions to become a leader in cell and gene therapies. A total of $15.4 References 1. About Ixaka.

Gene Therapy 40

Gene Therapy Gene In-Vivo Genetics 40

Drug Discovery World

NOVEMBER 28, 2022

By enabling immune cells to penetrate these immune-excluded tumours, Neobe is predicting that its products could double the number of cancer patients that respond to existing immunotherapies. . Neobe was founded by Pedro Correa de Sampaio and Annelise Soulier to address this significant unmet clinical need. .

Engineer 52

Engineer In-Vivo Genetics Production 52

Drug Discovery World

AUGUST 14, 2023

While CGT is still an emerging market, its growth has accelerated over the last five years, resulting in a wave of products approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). And the robust CGT pipeline suggests there could be an influx of new approvals on the horizon. billion in 2020 to $15.5

Gene Therapy 52

Gene Therapy Marketing Gene DNA 52

Roots Analysis

JANUARY 14, 2024

Overview of Biologics Biologics refer to medicinal / therapeutic products that are either manufactured using living organisms or semi-synthesized from biological sources. This can be attributed to the fact that the production of biopharmaceuticals requires living expression systems. Like all drugs, biologics are regulated by the FDA.

Contract Manufacturing 40

Contract Manufacturing Manufacturing Protein Bacteria 40